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Abstract 
Objective: We present the statistical analysis plan of a prespecified Tranexamic Acid for Hyperacute Primary Intrac-
erebral Haemorrhage (TICH)-2 sub-study aiming to investigate, if tranexamic acid has a different effect in intracer-
ebral haemorrhage patients with the spot sign on admission compared to spot sign negative patients. The TICH-2 
trial recruited above 2000 participants with intracerebral haemorrhage arriving in hospital within 8 h after symptom 
onset. They were included irrespective of radiological signs of on-going haematoma expansion. Participants were 
randomised to tranexamic acid versus matching placebo. In this subgroup analysis, we will include all participants in 
TICH-2 with a computed tomography angiography on admission allowing adjudication of the participants’ spot sign 
status.
Results: Primary outcome will be the ability of tranexamic acid to limit absolute haematoma volume on computed 
tomography at 24 h (± 12 h) after randomisation among spot sign positive and spot sign negative participants, 
respectively. Within all outcome measures, the effect of tranexamic acid in spot sign positive/negative participants will 
be compared using tests of interaction. This sub-study will investigate the important clinical hypothesis that spot sign 
positive patients might benefit more from administration of tranexamic acid compared to spot sign negative patients.
Trial registration ISRCTN93732214 (http://www.isrct n.com)
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Introduction
Limiting post-admission intraparenchymal haematoma 
expansion is one of the most promising targets for inter-
ventional research aiming to improve the functional out-
come after intracerebral haemorrhage (ICH). Multiple 
studies have shown that intraparenchymal haematoma 
expansion contributes to the acute neurological instabil-
ity of the patients [1–3] and poor long-term functional 
outcome [4, 5]. Data from the Intensive Blood Pressure 
Reduction in Acute Intracerebral Haemorrhage Trial 
(INTERACT) [5] estimated that post-admission intra-
parenchymal haematoma expansion increased the risk 
of death or dependency by 5% per millilitre additional 
haematoma volume. Hence limitation of intraparen-
chymal haematoma expansion would theoretically have 
a huge impact on outcome. In a population of patients 
with acute ICH, roughly 30% can be expected to undergo 
post-admission expansion of the intraparenchymal hae-
matoma depending on the timing of the scans and the 
definition of expansion utilised [6].
Post-admission expansion of the intraparenchymal 
haematoma may not only cause additional damage to 
local brain parenchyma. On-going bleeding within the 
intraparenchymal haematoma may also cause expansion 
of pre-existing intraventricular haematoma by allowing 
additional blood to leak into the ventricular system [7] 
(Fig. 1). Alternatively, in patients with no intraventricular 
haematoma on admission, post-admission intraparenchy-
mal haematoma expansion can result in decompression 
of the intraparenchymal haematoma into the ventricular 
system and the formation of a delayed intraventricular 
haematoma [8–10]. Consequently, impairing on-going 
bleeding within the intraparenchymal haematoma is 
likely to stabilise not only the intraparenchymal haema-
toma, but also the intraventricular haemorrhagic com-
ponent. A similar mechanism can be assumed for 
subarachnoid haemorrhagic extension.
The proposed strategy used to stabilize the haematoma 
in several on-going trials is the acute administration of 
a haemostatic agent. The Tranexamic Acid For Hypera-
cute Primary Intracerebral Haemorrhage (TICH)-2 trial 
[11] aims to investigate, whether acute administration of 
tranexamic acid can improve functional outcome after 
ICH. Previous trials on haemostatic agents in patients 
with acute ICH have shown that haematoma expansion 
can be significantly inhibited; however, no improvement 
in functional outcome has been shown [12]. It has been 
hypothesized that selecting patients with radiological 
signs of on-going haematoma expansion is essential, as 
only patients with on-going haematoma expansion can 
be expected to benefit from the administration of hae-
mostatic agents. On the other hand, patients without 
Fig. 1 The spot sign is generally understood to be a radiological visualisation of an actively bleeding ruptured blood vessel (b) causing 
intraparenchymal haematoma expansion and by extension expansion of the intraventricular haematoma (a). The actively bleeding ruptured vessel 
is visualised on CT-angiography as the spot sign. c Depicts an authentic CT-angiography image of an acute intracerebral haemorrhage patient. A 
relatively large spot sign can be observed within the haematoma. Significantly enlarged intraparenchymal and intraventricular haematomas can 
often be seen on follow-up imaging (d)
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on-going haematoma expansion may not benefit from a 
more stable haematoma, potentially leaving this patient-
group with only the risk of adverse events [13].
Even though the safety profile of tranexamic acid has 
in general been found to be good, one of the greatest 
theoretical concerns when administering a haemostatic 
agent is the risk of a thromboembolic event. The large 
CRASH-2 trial [14] did not confirm an increased risk 
of thromboembolic events in the group treated with 
tranexamic acid among acute trauma patients. How-
ever, previous trials randomising intracerebral haemor-
rhage patients to recombinant factor VII did observe 
an increased risk of thromboembolic events related to 
the treatment [12]. In addition, observational studies of 
intracerebral haemorrhage patients have observed a rela-
tive high prevalence of cerebral ischemic lesions, when 
the patients are scanned in the sub-acute period after 
symptom onset [15, 16]. This finding could indicate that 
the risk of cerebral ischemia could be relatively high in 
acute intracerebral haemorrhage patients suggesting a 
potential added risk of administering haemostatic agents.
The TICH-2 trial includes acute ICH patients regard-
less of radiological signs of on-going bleeding. The pre-
sent manuscript details a pre-specified sub-study of 
the TICH-2 trial aiming to explore, whether contrast 
enhanced radiological signs of on-going haematoma 
expansion can identify patients, who will benefit more 
from the administration of tranexamic acid, and whether 
patients with radiologically stable haematomas risk harm 
by adverse effects without the compensating benefit of 
limited haematoma expansion. In order to identify par-
ticipants with on-going haematoma expansion on admis-
sion, we will utilise the spot sign based on computed 
tomography angiography (CTA).
The predictive capability of the spot sign towards 
haematoma expansion has been confirmed in many 
studies. It has been hypothesized that the spot sign rep-
resents active leakage of blood from vessels adjacent to 
the haematoma and consequently represents on-going 
haematoma expansion (Fig. 1). In general, the specific-
ity of the spot sign is reported as good (meta-analysed 
specificity 0.88, confidence interval (CI) 0.86–0.89), 
whereas the sensitivity is reported as fair (meta-ana-
lysed sensitivity 0.53, CI 0.49–0.57) [17]. Two sepa-
rate systematic reviews have concluded that inferences 
regarding the reliability of the spot sign to predict hae-
matoma expansion could be influenced by poor or het-
erogeneous methodology and possibly publication bias 
[17, 18]. The scan protocol used when conducting CTA 
can also significantly influence the prevalence of the 
spot sign and its predictive capability towards haema-
toma expansion [19]. Spot signs observed in the venous 
phase are more prevalent, but its prediction towards 
haematoma expansion is poorer compared to spot signs 
observed in the arterial phase. Besides the spot sign 
on CTA, extravasation of contrast on post-contrast 
computed tomography can predict haematoma expan-
sion even in spot sign negative patients [20, 21]. Even 
though the spot sign, like all other biomarkers, has its 
limitations, it remains the most widely investigated and 
clinically established predictor of on-going haematoma 
expansion in acute intracerebral haemorrhage patients.
Primary research question
This TICH-2 sub-study aims to investigate, whether 
the spot sign on CTA can identify patients with a 
high chance of benefit from acute administration of 
tranexamic acid.
Main trial design
The present manuscript describes a pre-specified sub-
group study of the TICH-2 trial (http://www.tich-2.org).
The TICH-2 trial is an international placebo-con-
trolled, blinded, randomised trial aiming at determin-
ing, whether administration of tranexamic acid versus 
placebo to participants with spontaneous intracerebral 
haemorrhage is able to reduce death and dependency at 
3 months.
The protocol for the TICH-2 trial has already been pub-
lished [11]. In brief, the TICH-2 trial randomises adult 
patients with acute spontaneous ICH arriving in hospi-
tal within 8 h after stroke onset to either 2 g tranexamic 
acid versus matching placebo. The participants are ran-
domised after diagnostic non-contrast computed tomog-
raphy (CT) scan (and optionally CTA) has revealed a 
spontaneous intracerebral haemorrhage. Participants are 
randomised in a 1:1 ratio using an adaptive randomisa-
tion procedure minimising differences between treat-
ment arms with regard to age, sex, time from onset to 
randomisation, mean systolic blood pressure, stroke 
severity, presence of intraventricular haemorrhage, and 
known history of antiplatelet treatment. The randomisa-
tion procedure stratifies the allocation for country.
Two grams of tranexamic acid or matching placebo is 
administered as an intravenous infusion over 8  h. The 
participant is then observed and treated in the hospital 
as per local guidelines. Twenty-four hours (± 12 h) after 
admission, a 24-h CT will provide the final haematoma 
volume. After a period of 3 months, the participant/car-
egiver will be contacted by telephone in order to assess 
the participant’s functional outcome/mortality.
The TICH-2 trial will include at least 2000 participants. 
The primary outcome of the TICH-2 trial is death or 
dependency at day 90.
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Main text
Analysis population and missing data
The TICH-2 main population will be analysed using 
the intention-to-treat principle. All randomised par-
ticipants will be included in the present sub-group 
analysis, provided they have undergone an admission 
CTA allowing the spot sign status to be assessed and 
not having withdrawn consent within the first 24  h. 
The sample size of this sub-study will be determined by 
enrolment in the TICH-2 study. Missing minimisation 
criteria and missing data will be handled as indicated 
in the TICH-2 main statistical analysis plan (SAP) [22].
Outcomes
For all outcome analysis, the population of participants 
will be separated into two subgroups—with and with-
out spot sign on CTA. Within each of the spot sign 
groups, we will compare the mean difference/probabil-
ity of the outcome between participants allocated to 
tranexamic acid versus placebo adjusting for minimisa-
tion and stratification factors. The homogeneity of the 
effect estimates (spot sign positive compared to spot 
sign negative) will be analysed by interaction-tests.
Primary outcome
Absolute intraparenchymal haematoma volume on 24-h 
(± 12 h) CT (or if 24-h CT is not available or biased, a 
CT obtained after randomisation but before the day-2 
scan window will be used). The primary outcome will 
also be analysed as intraparenchymal haematoma com-
bined with intraventricular haematoma.
All randomised participants will be included in the 
primary analysis, provided that they have a 24-h CT 
performed (or if 24-h CT is not available or biased, a 
CT obtained after randomisation but before the 24-h 
(± 12 h) scan window will be used). Biased 24-h CT will 
be defined as a 24-h CT obtained after surgical proce-
dures aiming at total or partial removal of intraparen-
chymal or intraventricular haematoma.
Secondary outcomes
• Dichotomous haematoma progression defined as 
a composite outcome. The proposed dichotomous 
composite outcome is necessary in order to avoid 
bias by limiting the population to participants fit 
enough to have a per-protocol 24-h CT performed. 
It is likely that a considerable group will either die 
or undergo surgical procedures, prior to the per-
protocol 24-h CT can be obtained. It is further 
likely that this group will not be distributed at ran-
dom yielding a large risk of bias and reduction of 
external validity.
 The following will constitute haematoma progression 
on 24-h CT (± 12 h) relative to the admission CT:
∘ Intraparenchymal haematoma expansion (≥ 6 mL 
absolute expansion or/and 33% relative expan-
sion), and/or∘ Delayed intraventricular or subarachnoid haem-
orrhagic extension, and/or∘ Intraventricular haematoma expansion (≥ 2  mL 
absolute expansion).
 In case the per-protocol 24-h CT is biased 
(defined as partial or complete surgical removal 
of haematoma) or not available (caused by do-
not-resuscitate orders, withdrawal-of-care 
orders, death, or protocol violation), the follow-
ing will be classified as haematoma progression in 
the outcome analysis:
∘ Expansion of either intraventricular or intra-
parenchymal haematoma (as defined above) or 
delayed intraventricular or subarachnoid haem-
orrhagic on emergency CT obtained after ran-
domisation but before the 24-h (± 12  h) scan 
time window (the same definitions of expansion 
will apply, as if they were observed on the per-
protocol 24-h CT), and/or∘ Early neurological deterioration or death between 
admission and the day-2 clinical assessment.
• In order to ascertain, if the treatment effect measured 
by the composite outcome is being driven be any of 
the different components in particular, analysis of the 
individual components will be conducted.
• Serious adverse event within the first 7  days after 
randomisation.
• Safety outcome within the first 90  days after ran-
domisation.
• Thromboembolic event within the first 90 days after 
randomisation.
• Day-90 modified Rankin scale will be analysed as a 
dichotomous poor outcome (modified Rankin Scale 
4–6).
• Day-90 Barthel Index will be analysed as a continu-
ous outcome.
• Mortality at day-90.
Please confer definitions listed in Additional file 1.
Power estimations
As acute CTA does not represent standard-of-care in 
the evaluation of ICH-patients in all countries, only a 
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subpopulation of randomised participants in the TICH-2 
trial can be expected to have had one performed. We 
estimate that approximately 60 spot sign positive par-
ticipants (30 allocated to tranexamic acid and 30 to pla-
cebo) will be included. We also estimate that 10% will 
have missing or biased 24-h CT. This yields a probability 
of rejecting the primary outcome null hypothesis [mean 
difference (MD) 14 mL, standard deviation (SD) 17 mL, 
α-level 0.05] [23] that tranexamic acid does not prevent 
haematoma expansion in spot sign positive participants 
of 84%.
We also estimate that approximately 180 spot sign 
negative participants will be included (90 allocated to 
tranexamic acid and 90 to placebo). We estimate that 
10% will have missing 24-h CT. This yields a probability 
of rejecting the primary outcome null hypothesis (MD 
2  mL, SD 8  mL, α-level 0.05) [23] that tranexamic acid 
does not prevent haematoma expansion in spot sign neg-
ative participants of 35%.
In order to estimate the power of the test of interaction 
between spot sign status and allocation (tranexamic acid 
versus placebo), we used the user written program ‘Pow-
ersim’ [24]. We used a MD of 12 mL and a SD of 14 mL 
for all effects, together with a risk of type 1 error of 5%, 
which resulted in an estimated power of 85%. Power cal-
culations for secondary outcomes are presented in Addi-
tional file 2.
Statistical methodology
Regression models will be used to analyse primary 
and secondary outcomes in order to allow for adjust-
ment whenever appropriate. For all outcomes, an effect 
size (tranexamic acid versus placebo) will be calculated 
for participants with and without spot sign on admis-
sion. The two effect sizes will be compared using a test 
of interaction. Multivariable analyses will be undertaken 
adjusting effect estimates for minimization and stratifica-
tion factors. As the sample of especially spot sign positive 
participants is relatively small, we recognise the potential 
risk of over-fitting the model, if the models are adjusted 
for all minimization factors. If such a situation arrives, 
we will limit the number of covariates in the analysis to 
those of particular importance including age, time from 
stroke onset to treatment, and stroke severity (admis-
sion National Institute of Health Stroke Scale), as these 
have been consistently shown to be related to outcome 
[13, 25]. The number of observations deemed necessary 
in order to reduce the risk of over-fitting the models is 
presented in Additional file 3. We will consequently pre-
sent a set of analyses adjusted for the at least three above-
mentioned minimization factors, and if sample size 
permits, another set of analysis will be provided with all 
the minimisation factors included. The model building 
will be discussed in final publication.
The following models will be used:
• In analysing the primary outcome, the main param-
eter of interest will be the mean difference in absolute 
haematoma volume on 24-h (± 12  h) CT between 
participants randomised to tranexamic acid versus 
placebo adjusted for baseline haematoma volume [26, 
27]. This outcome will be analysed using multiple lin-
ear regression.
• The secondary composite outcome, serious adverse 
events, safety events and thromboembolic event will 
be analysed using binary logistic regression.
• Day-90 Barthel Index will be analysed using multiple 
linear regression.
• Day-90 dichotomous modified Rankin scale will be 
analysed using binary logistic regression.
• Mortality within the first 90-days will be analysed 
using Cox proportional hazard model.
An important assumption in statistical procedures is 
independence of observations. This assumption is often 
violated, as correlation often exists between clusters of 
participants, in which participants share more charac-
teristics than participants between clusters [28]. This 
is especially the case, when randomisation procedures 
stratify the allocation according to some entity—e.g. hos-
pital or country. Overlooking this correlation structure 
can lead to too narrow confidence intervals [28, 29]. In 
the supplements of our final report, we will repeat the 
above specified analysis using generalized estimating 
equation (linear and logistic) with non-robust standard 
error [29, 30] in order to account for the cluster-effect 
of country as the minimization procedure was stratified 
for country. Differences in reached conclusions will be 
discussed.
For all regression models used, we will carefully report, 
how fulfilment of underlying assumptions was assessed. 
The statistical assumptions are presented in Additional 
file 3.
Statistical inferences
Oxman et  al. [31] proposed a number of stipulations 
guiding the trustworthiness of sub-group analysis of 
randomised trials. This TICH-2 subgroup analysis is a 
pre-specified analysis, which underlying hypothesis is 
supported by our pathophysiological understanding of 
the spot signs predictive capability towards haematoma 
expansion. An interaction between the spot sign sta-
tus and the pharmacological effect of tranexamic acid 
in limiting the primary outcome is an important clinical 
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hypothesis and can ideally be studied in this setting, as 
both spot sign positive and negative participants are 
treated within the same trial and hence following the 
same protocol [31]. This increases the validity of the clin-
ical and statistical inferences made on the basis of this 
analysis.
In this study, an analysis will be considered statistically 
significant, if the probability of type 1 error is less than 
5% (2-sided). As we recognise that the statistical power 
of the interaction-test testing the homogeneity of the 
treatment response between participants with and with-
out spot sign will likely have a low power, the inferences 
drawn from this sub-group analysis will be exploratory in 
nature [32, 33]. Simulation-studies have shown that infla-
tion of the original sample size is often necessary to main-
tain the power of the main primary outcome (often 80 
or 90%) in the sub-group analysis [33]—hence this sub-
group analysis will theoretically contain an enlarged risk 
of false-negative findings, even though simulation-based 
power analysis indicates an acceptable power for the pri-
mary outcome of this sub-group analysis. To obtain a suf-
ficient power, the present sub-group analysis might need 
to be included in meta-analysis with other on-going stud-
ies. At least two other trials (STOP-AUST and TRAIGE) 
are currently randomising spot sign positive participants 
with intracerebral haemorrhage to either tranexamic 
acid or placebo (ClinicalTrial.gov NCT01702636 and 
NCT02625948, accessed November 2017) [34–36].
For the secondary outcomes, the risk of multiplicity 
implies. In case of an insignificant primary outcome in 
both participants with and without spot sign on admis-
sion scan, no effort will be undertaken to control the 
inflation of type 1 error due to multiplicity in the second-
ary outcomes, as no isolated direct clinical inferences will 
be drawn from them—however, their significance will be 
discussed.
After the statistical analysis, we will thoroughly assess 
the clinical significance of the results [37].
Definitions
Definitions are presented in Additional file 1.
Pre‑planned tables and figures
Pre-planned tables and figures are presented in Addi-
tional file 4.
Discussion
We have above presented the statistical analysis plan 
for the spot sign sub-study of the TICH-2 trial. As 
elaborated, such sub-studies might have archived a 
bad reputation for being potentially misleading, data-
driven, and underpowered [31]. However, we believe 
that since the underlying hypothesis is supported by 
our pathophysiological understanding of the spot sign, 
the sub-group analysis is pre-planned, and the method-
ology is sought to be as rigorous as possible, we will be 
able to archive methodological quality in our analysis. 
Currently, other trials are randomising spot sign posi-
tive ICH patients to tranexamic acid versus placebo 
[34–36]. The data of this subgroup-analysis will be 
highly interesting for inclusion in meta-analysis with 
these forthcoming trials.
The primary outcome will be mean difference in 
24-h absolute haematoma volume compared between 
participants allocated to tranexamic acid versus pla-
cebo, adjusted for haematoma volume at baseline. We 
choose to analyse the 24-h absolute haematoma volume 
(adjusted for baseline haematoma volume) instead of 
analysing a measure of change from baseline (e.g. mil-
lilitre haematoma expansion or per cent volume expan-
sion). Studies have shown that measures of change can 
potentially be biased, if baseline differences in haema-
toma volume exist between treatment groups and that 
measures of change can yield lower statistical power 
[26, 27]. The continuous outcome of 24-h absolute hae-
matoma volume was chosen as the primary outcome 
as this outcome yielded the highest calculated statisti-
cal power. However, due to the poor clinical condition 
of a relatively large proportion of intracerebral haem-
orrhage patients, it must be expected that some of the 
participants in the trial will have missing day-2 scans 
excluding them from the primary outcome analysis. 
Anticipating this, we designed the secondary compos-
ite outcome of haematoma progression.
Limitations
As discussed above, one should always be cautious in 
drawing firm conclusions from sub-studies, especially 
when it comes to making clinical recommendations. 
A clear limitation of this study is its possibility of gen-
erating results of low external validity. Participants 
are recruited into this sub-study, based on whether 
they have had a CT-angiography performed on admis-
sion. As the CT-angiography is not standard-of-care 
in many centres, it is likely that the participants, who 
had a CT-angiography performed, are systematically 
different from the rest of the TICH-2 population. We 
believe that this fact emphasises that inferences drawn 
from this study need confirmation in other trials. It 
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is consequently the hope of the authors that this sub-
study can be hypothesis-generating, and can inform 
future trialists when designing trials assessing the 
effect of tranexamic acid in intracerebral haemorrhage 
patients.
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